8 results
Algorithm for the Evaluation of Anemia #Diagnosis #EM #IM #Honc #Anemia #Differential #Workup #Algorithm #Microcytic #Macrocytic
Algorithm for the ... Anemia #Diagnosis #EM ... #IM #Honc #Anemia ... Differential #Workup #Algorithm
Evaluation of Lymphadenopathy - Localized vs Generalized #Diagnosis #EM #IM #Honc #Lymphadenopathy #Localized #Generalized #Infectious #Malignancy
Generalized #Diagnosis #EM ... #IM #Honc #Lymphadenopathy ... #Differential #Algorithm
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free ... Survival #EBM #Honc ... NSCLC #Survival #NEJM
IgM and Non-IgM - Risk and Type of Progression #EBM #Honc #MGUS #Progression #IgM #NonIgM #MultipleMyeloma
Risk and Type of Progression ... #EBM #Honc #MGUS ... #Progression #IgM ... MultipleMyeloma #NEJM
Cumulative Incidence of Progression of MGUS, with Death Accounted for as a Competing Risk #EBM #Honc
Cumulative Incidence of Progression ... Competing Risk #EBM #Honc ... #MGUS #Progression ... #IgG #MGUS #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
Lung Cancer - Progression-free ... #EBM #Honc #PACIFIC ... Durvalumab #NSCLC #NEJM
Diffuse Melanosis Cutis - Several weeks earlier, a progressive gray–blue discoloration of the skin had developed.
weeks earlier, a progressive ... Clinical #Derm #Honc ... Hyperpigmentation #NEJM
Diagnostic Algorithm for Non–Small-Cell Lung Cancer (NSCLC). The upper portion of the algorithm shows the morphologic
Diagnostic Algorithm ... portion of the algorithm ... #Diagnosis #Honc ... #Algorithm #NSCLC ... #PDL1 #NEJM